Activity of Lefamulin, an Pleuromutilin Derivative, against S. aureus Strains with Decreased Susceptibility to Vancomycin
Activity of Lefamulin, an Pleuromutilin Derivative, against S. aureus Strains with Decreased Susceptibility to Vancomycin, Lead author: Sader HS, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Oritavancin In Vitro Activity Against a Collection of Molecularly-characterized Staph and Enterococci with Elevated Linezolid MICs
Oritavancin In Vitro Activity Against a Collection of Molecularly-characterized Staph and Enterococci with Elevated Linezolid MICs, Lead author: Mendes RE, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Report of Linezolid Activity from the ZAAPS Program 2014 (EU, LA, APAC, Cananda)
Report of Linezolid Activity from the ZAAPS Program 2014 (EU, LA, APAC, Cananda), Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Activity of Solithromycin Against Pathogens Associated with CABP: Global Surveillance Results from 2014
Activity of Solithromycin Against Pathogens Associated with CABP: Global Surveillance Results from 2014, Lead author: Farrell DJ, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Performance of BD MAX™ StaphSR against S. aureus Clinical Isolates from the 9 USA Census Regions
Performance of BD MAX™ StaphSR against S. aureus Clinical Isolates from the 9 USA Census Regions, Lead author: Mendes RE, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Solithromycin MIC and Disk Diffusion Quality Control Ranges, a CLSI Multi-Laboratory M23-A3 Study Design
Solithromycin MIC and Disk Diffusion Quality Control Ranges, a CLSI Multi-Laboratory M23-A3 Study Design, Lead author: Ross JE, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Ceftobiprole Activity When Tested Against Clinical Bacterial Pathogens from Europe, Turkey and Israel 2014
Ceftobiprole Activity When Tested Against Clinical Bacterial Pathogens from Europe, Turkey and Israel 2014, Lead author: Farrell DJ, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Activity of Omadacycline Tested against Enterobacteriaceae Causing Urinary Tract Infections from a Global Surveillance Porgram (2014)
Activity of Omadacycline Tested against Enterobacteriaceae Causing Urinary Tract Infections from a Global Surveillance Porgram (2014), Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Activity of a Long-acting Echincandin (CD101) and Comparator Antifungal Agents against Contemporary Invasive Fungal Isolates
Activity of a Long-acting Echincandin (CD101) and Comparator Antifungal Agents against Contemporary Invasive Fungal Isolates, Lead author: Castanheira M, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
In Vitro Activity of Pexiganan Tested Against Pathogens with Elevated MICs to Topical Antimicrobials
In Vitro Activity of Pexiganan Tested Against Pathogens with Elevated MICs to Topical Antimicrobials, Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Evaluation of Carbapenemase Detection Methods Using a Challenging Collection of Enterobacteriaceae Isolates
Evaluation of Carbapenemase Detection Methods Using a Challenging Collection of Enterobacteriaceae Isolates, Lead author: Castanheira M, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Activity of Omadacycline Tested Against S. aureus from a Global Surveillance Program (2014)
Activity of Omadacycline Tested Against S. aureus from a Global Surveillance Program (2014), Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Plazomicin (PLZ) Activity Against Contemporary Clinical Isolates Collected in USA Hospitals
Plazomicin (PLZ) Activity Against Contemporary Clinical Isolates Collected in USA Hospitals, Lead author: Castanheira M, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
In vitro Activity of Tedizolid Against Gram-positive Pathogens Isolated from Patients SSSI in the US and EU During 2014
In vitro Activity of Tedizolid Against Gram-positive Pathogens Isolated from Patients SSSI in the US and EU During 2014, Lead author: Farrell DJ, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Tigecycline activity tested against >11,000 isolates of Acinetobacter spp. collected worldwide in 2004-2013
Tigecycline activity tested against >11,000 isolates of Acinetobacter spp. collected worldwide in 2004-2013, Lead author: Sader HS, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Update on dalbavancin activity tested against Gram-positive isolates causing documented skin and soft tissue infections in USA and European hospitals (2011-2013)
Update on dalbavancin activity tested against Gram-positive isolates causing documented skin and soft tissue infections in USA and European hospitals (2011-2013), Lead author: Medes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Antimicrobial potency of lefamulin (BC-3781) tested against S. pneumoniae with defined serotypes, including MDR isolates causing lower RTI in the USA
Antimicrobial potency of lefamulin (BC-3781) tested against S. pneumoniae with defined serotypes, including MDR isolates causing lower RTI in the USA, Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Minocycline activity tested against A. baumannii, B. cepacia, S. maltophila, and select Enterobacteriaceae isolates from a European surveillance program (2013)
Minocycline activity tested against A. baumannii, B. cepacia, S. maltophila, and select Enterobacteriaceae isolates from a European surveillance program (2013), Lead author: Flamm RK, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Sustained potent activity of dalbavancin when tested against MDR staphylococcal and streptococcal isolates responsible for documented infection in EU (2011-2013)
Sustained potent activity of dalbavancin when tested against MDR staphylococcal and streptococcal isolates responsible for documented infection in EU (2011-2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Oritavancin in vitro activity against the most prevalent antibiogram resistance patterns among MRSA, including MDR strains from patients in European hospitals (2010-2013)
Oritavancin in vitro activity against the most prevalent antibiogram resistance patterns among MRSA, including MDR strains from patients in European hospitals (2010-2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
In vitro activity of oritavancin against streptococci, including macrolide- and/or lincosamide (constitutive)-resistant and MDR isolates from EU hospitals (2010-2013)
In vitro activity of oritavancin against streptococci, including macrolide- and/or lincosamide (constitutive)-resistant and MDR isolates from EU hospitals (2010-2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
In vitro activity of dalbavancin tested against S. pneumoniae responsible for documented infection in medical centres in five continents worldwide (2011-2013)
In vitro activity of dalbavancin tested against S. pneumoniae responsible for documented infection in medical centres in five continents worldwide (2011-2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Accuracy of Predicting Oritavancin Susceptibility using Vancomycin Surrogate Susceptibility Testing of GP from EU
Accuracy of Predicting Oritavancin Susceptibility using Vancomycin Surrogate Susceptibility Testing of GP from EU, Lead author: Jones RN, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Molecular characterization of genes encoding CTX-M-134, TEM-207 and TEM-212 detected among Escherichia coli clinical isolates from USA hospitals
Molecular characterization of genes encoding CTX-M-134, TEM-207 and TEM-212 detected among Escherichia coli clinical isolates from USA hospitals, Lead author: Castanheira M, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Maximizing antibacterial activity of polymyxin B: Microbiological component analyses alone and in combination
Maximizing antibacterial activity of polymyxin B: Microbiological component analyses alone and in combination, Lead author: Kassamali Z, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Potent in vitro activity of telavancin against EU strep. isolates displaying an array of antibiogram profiles
Potent in vitro activity of telavancin against EU strep. isolates displaying an array of antibiogram profiles, Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Antimicrobial Activity of Ceftolozane/Tazobactam and Comparator Agents Tested against Pseudomonas aeruginosa Isolates from 15 European Countries and Israel (2013)
Antimicrobial Activity of Ceftolozane/Tazobactam and Comparator Agents Tested against Pseudomonas aeruginosa Isolates from 15 European Countries and Israel (2013), Lead author: Sader HS, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Antimicrobial Activity of Ceftolozane/Tazobactam and Comparator Agents Tested against Enterobacteriaceae Isolates from 15 European Countries and Israel (2013)
Antimicrobial Activity of Ceftolozane/Tazobactam and Comparator Agents Tested against Enterobacteriaceae Isolates from 15 European Countries and Israel (2013), Lead author: Farrell DJ, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Update of the telavancin in vitro activity against SA and CoNS, including isolates with decreasing susceptibility for comparator agents in European hospitals (2013)
Update of the telavancin in vitro activity against SA and CoNS, including isolates with decreasing susceptibility for comparator agents in European hospitals (2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Debio 1452 MIC QC Range with S. aureus ATCC 29213 Using a Multi-laboratory Study Design
Debio 1452 MIC QC Range with S. aureus ATCC 29213 Using a Multi-laboratory Study Design, Lead author: Flamm RK, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark
Initial broth microdilution quality control guidelines for Debio 1452, a FabI inhibitor antimicrobial agent.
Initial broth microdilution quality control guidelines for Debio 1452, a FabI inhibitor antimicrobial agent. by Ross JE, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (11): 7151-7152
Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012.
Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012. by Mendes RE, Hollingsworth RC, Costello A, Jones RN, Isturiz RE, Hewlett D, Jr. and Farrell DJ published in Antimicrob. Agents. Chemother. 2015; 59 (9): 5595-5601
Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin.
Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin. by Mendes RE, Farrell DJ, Flamm RK, Sader HS and Jones RN published in J. Clin. Microbiol. 2015; 53 (8): 2727-2730
Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: Redefining the baseline activity of telavancin.
Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: Redefining the baseline activity of telavancin. by Mendes RE, Flamm RK, Farrell DJ, Sader HS and Jones RN published in J. Chemother. 2016; 28 (2): 83-88
Determination of disk diffusion and MIC quality control guidelines for solithromycin, a novel fluoroketolide antibacterial against Neisseria gonorrhoeae.
Determination of disk diffusion and MIC quality control guidelines for solithromycin, a novel fluoroketolide antibacterial against Neisseria gonorrhoeae. by Riedel S, Ross JE, Farrell DJ, Flamm RK and Jones RN published in J. Clin. Microbiol.: 2015; 53 (12): 3888-3890
Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).
Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). by Sader HS, Castanheira M, Farrell DJ, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 83 (4): 389-394
In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative pathogens.
In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative pathogens. by Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF and Bradford PA published in Antimicrob. Agents. Chemother. 2015; 59 (10): 6053-6063
Detection of a new cfr-like gene, cfr(B), in Enterococcus faecium recovered from human specimens in the United States: Report from The SENTRY Antimicrobial Surveillance Program.
Detection of a new cfr-like gene, cfr(B), in Enterococcus faecium recovered from human specimens in the United States: Report from The SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Ashcraft DS, Kahn HP, Pankey G, Jones RN, Farrell DJ and Mendes RE published in Antimicrob. Agents. Chemother. 2015; 59 (10): 6256-6261,
Genotypic characterization of methicillin-mesistant Staphylococcus aureus recovered at baseline from Phase 3 pneumonia clinical trials for ceftobiprole.
Genotypic characterization of methicillin-mesistant Staphylococcus aureus recovered at baseline from Phase 3 pneumonia clinical trials for ceftobiprole. by Mendes RE, Deshpande LM, Costello AJ, Farrell DJ, Jones RN and Flamm RK published in Microb. Drug Resist.: 2016; 22 (1): 53-58,
Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013).
Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013). by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in J. Global Antimicrob. Res. 2015; 3 (1): 36-39
Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13).
Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13). by Sader HS, Farrell DJ, Flamm RK and Jones RN. published in J. Antmicrob. Chemother. 2015; 70 (7): 2053-2056,
Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013).
Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in J. Global. Antimicrob. Res. 2015; 3: 161-165
Microbiological assessment of polymyxin B components tested alone and in combination.
Microbiological assessment of polymyxin B components tested alone and in combination. by Kassamali Z, Prince RA, Danziger LH, Rotschafer JC, Rhomberg PR and Jones RN published in Antimicrob. Agents. Chemother. 2015; 59 (12): 7823-7825
Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide.
Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. by Sader HS, Rhomberg PR, Farrell DJ and Jones RN. published in Diagn. Microbiol. Infect. Dis. 2015; 83 (4): 379-381.
Telavancin in vitro activity against a USA collection of methicillin-resistant Staphylococcus aureus, including resistant subsets.
Telavancin in vitro activity against a USA collection of methicillin-resistant Staphylococcus aureus, including resistant subsets. by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (3): 1811-1814
Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.
Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. by Penwell WA, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband M, DeJonge BL, Ehmann DE and Miller AA published in Antimicrob. Agents Chemother. 2015; 59 (3): 1680-1689
Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.
Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. by Sader HS, Farrell DJ, Mendes RE, Flamm RK, Castanheira M and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 82 (1): 78-84
Validation of a commercial dry-form broth microdilution device (Sensititre®) for testing tedizolid, a new oxazolidinone.
Validation of a commercial dry-form broth microdilution device (Sensititre®) for testing tedizolid, a new oxazolidinone. by Jones RN, Holliday NM and Rhomberg PR published in J. Clin. Microbiol. 2015; 53 (2): 657-659
Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-2013).
Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-2013). by Mendes RE, Farrell DJ, Sader HS, Flamm RK and Jones RN published in J. Antimicrob. Chemother. 2015; 70 (2): 498-504
Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying the revised susceptibility testing method.
Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying the revised susceptibility testing method. by Mendes RE, Farrell DJ, Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (1): 702-706
